New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
07:14 EDTRHHBY, ABBV, PCYCAbbVie, Roche drug a real threat to Pharmacyclics, says Bernstein
After analyzing abstracts from the ASCO conference, Bernstein believes that ABT199, a treatment for CLL from Roche (RHHBY) and AbbVie (ABBV), is a "real threat" to Pharmacyclics' (PCYC) Imbruvica. However, the firm continues to believe that Imbruvica is impressive due to its duration of effect. It keeps an Outperform rating on Roche and a Market Perform rating on Pharmacyclics.
News For ABBV;RHHBY;PCYC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 21, 2014
09:48 EDTABBVShire could target BioMarin, TheStreet's Feuerstein says
Subscribe for More Information
07:15 EDTRHHBYFDA to hold workshop on breast cancer drug development
Subscribe for More Information
06:34 EDTABBVAbbVie downgraded to Neutral from Buy at Guggenheim
Subscribe for More Information
October 20, 2014
18:51 EDTABBVOn The Fly: After Hours Movers
Subscribe for More Information
18:49 EDTABBVEnanta will not exercise co-development option for ABT-493
Enanta Pharmaceuticals (ENTA) announced that it has decided not to exercise its co-development option for ABT-493, Enanta’s next-generation protease inhibitor for hepatitis C virus, or HCV, being developed in Enanta’s collaboration with AbbVie (ABBV). Per the original collaboration agreement signed in December 2006, Enanta will be eligible for certain regulatory approval milestones as well as royalties on net sales allocable to ABT-493 from worldwide sales of any ABT-493-containing regimens. Enanta also announced that it has reached agreement with AbbVie regarding the net sales allocations for royalty calculations for ABT-450-containing regimens, as well as any regimens containing ABT-493. ABT-450 is the first clinical-stage protease inhibitor candidate developed within the Enanta-AbbVie collaboration, and ABT-493 is the second.
17:34 EDTABBVAbbVie announces new $5B stock repurchase program, raises dividend nearly 17%
Subscribe for More Information
17:33 EDTABBVAbbVie announces new $5B stock repurchase program, raises dividend
17:26 EDTABBVShire down 1% following termination of merger with AbbVie
Subscribe for More Information
17:17 EDTABBVAbbVie to pay Shire $1.64B break fee
Subscribe for More Information
17:16 EDTABBVAbbVie, Shire announce termination of proposed merger
Subscribe for More Information
17:14 EDTABBVAbbVie, Shire announce termination of proposed merger
12:37 EDTRHHBYOn The Fly: Midday Wrap
Subscribe for More Information
08:14 EDTPCYCPharmacyclics files supplmeental NDA for Imbruvica for macroglobulinemia
Pharmacyclics (PCYC) announced that it has submitted a supplemental New Drug Application to the FDA based on data from a Phase 2 study evaluating the use of IMBRUVICA in patients with Waldenstrom's macroglobulinemia. IMBRUVICA, which received FDA Breakthrough Therapy Designation in February 2013 for patients with WM, is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech (JNJ).
07:47 EDTABBVPfizer less likely to renew Astra pursuit after Shire deal breakdown, FT says
Subscribe for More Information
07:19 EDTRHHBYIBC Life Sciences to hold a conference
Subscribe for More Information
07:11 EDTRHHBY, ABBVAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
07:10 EDTRHHBYAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
07:06 EDTRHHBYNewLink announces worldwide license agreement for NLG919 development
Subscribe for More Information
07:04 EDTRHHBYRoche approval would be positive for TESARO, says Jefferies
Subscribe for More Information
06:56 EDTABBVShire reopens acquistion talks with NPS Pharmaceuticals, Cubist, Telegraph says
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use